quantikine human vegf a elisa kit  (R&D Systems)

Journal: Ophthalmology Science

Article Title: Serial Aqueous Humor Proteomics in Diabetic Macular Edema

doi: 10.1016/j.xops.2025.101056

Figure Lengend Snippet: Abundance of proteins significantly associated with incomplete response to anti-VEGF therapy. A total of 10 proteins were found to be significantly regulated in substantial edema versus no edema. A, Upregulated proteins determined by mass spectrometry at time points 1 to 3 (T1-T3) included afamin (AFM), alpha-1B-glycoprotein (A1BG), and angiotensinogen (AGT). B, Downregulated proteins included cystatin-C (CST3), clusterin (CLU), apolipoprotein E (APOE), epidermal growth factor-containing fibulin-like extracellular matrix protein (EFEMP1), Ig lambda chain V-I (IGLV1), latent transforming growth factor beta-binding protein 2 (LTBP2), and reelin (RELN). C, The increased level of afamin was confirmed by ELISA. D, VEGFA concentration assessed by ELISA. There was no significant difference in VEGFA between the substantial edema and no edema groups. Box plots indicate median, min and max and first and third quartiles. ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001. ELISA = enzyme-linked immunosorbent assay; LFQ = Label-Free Quantification.

Article Snippet: Samples were diluted 500-fold for afamin (ELH-AFM-1, RayBiotech) and 2-fold for VEGFA (DVE00, R&D Systems).

Techniques: Mass Spectrometry, Binding Assay, Enzyme-linked Immunosorbent Assay, Concentration Assay, Quantitative Proteomics

Journal: Cell Communication and Signaling : CCS

Article Title: The Galectin-3-binding protein promotes angiogenesis in pancreatic cancer via simultaneous upregulation of VEGFA and direct HUVEC activation mediated by and VAMP5-STAT3

doi: 10.1186/s12964-026-02801-7

Figure Lengend Snippet: Gal-3BP positively regulates VEGFA production in PDAC. A . Clustered heatmap of the protein expression profile for PDX_PC 110,621 treated with rhGal-3BP, rhEGF, or rhGal-3BP+rhEGF combination. Red indicates upregulated protein levels, whereas green shows downregulated cases. The bottom panel indicates the VEGFA-VEGFR2 pathway enriched in C1 cluster, as shown by WikiPathway 2021 analysis. B and C . mRNA ( B ) and protein expression ( C ) of VEGFA in PDX_PC 110,621 after Gal-3BP knockdown by shRNA. D . VEGFA secretion measured by ELISA in PDX_PC 110,621 after Gal-3BP knockdown. E . The secretion of VEGFA measured in Panc-1 cells after Gal-3BP overexpression. F . Transwell migration of HUVEC co-cultured with control PDX_PC 110,621 or with Gal-3BP knockdown. The graph on right shows relative migration rate. Scale bar: 50 μm. G – H . Expression correlation analysis between Gal-3BP and VEGFA for mRNA ( G ) or protein ( H ), using cBioportal database.* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001; ns (not significant)

Article Snippet: Secreted VEGF was detected using the Human VEGF ELISA Kit (DVE00, R&D Systems).

Techniques: Expressing, Knockdown, shRNA, Enzyme-linked Immunosorbent Assay, Over Expression, Migration, Cell Culture, Control

Journal: Scientific Reports

Article Title: An MIEN1-based hexamer peptide (LA3IK) inhibits EGF-driven oncogenic signaling in prostate cancer by disrupting EGFR–ERBB2 heterodimerization

doi: 10.1038/s41598-026-41933-1

Figure Lengend Snippet: Time-Course Analysis of Angiogenesis Gene Regulation in PC3 Cells Upon EGF Stimulation and LA3IK Treatment. ( A ) Time-course heatmap showing upregulation of angiogenesis-related genes in PC3 cells following EGF stimulation at 0 h, 30 min, 1 h, and 6 h. ( B ) :(B) Heat-map displaying, for each gene, the log₂ fold-change induced by 6 h EGF versus 0 h (red ) and the subsequent log₂ fold-change observed when LA3IK was co-treated for 6 h versus EGF alone (blue) ( C ) Principal Component Analysis (PCA) plot showing the clustering and separation of RNA-seq samples from control (EGF 0 h), EGF-treated (6 h), and EGF + LA3IK-treated (6 h) in PC3 cells. ( D ) Combined RNA-seq and qPCR analysis showing LA3IK-mediated inhibition of ANGPTL4 expression. ( E ) Combined RNA-seq and qPCR analysis demonstrating reduced VEGFA expression upon LA3IK treatment. (E) ELISA quantification of secreted ANGPTL4 showing inhibition by LA3IK in EGF-treated PC3 cells. ( F ) ELISA analysis of ANGPTL4 levels showing time-dependent inhibition by LA3IK following EGF stimulation. ( G ) ELISA analysis of VEGFA levels showing time-dependent inhibition by LA3IK following EGF stimulation. For panels D and E, data were analyzed using a two-tailed Mann–Whitney test (nonparametric, unpaired). For F and G, a two-tailed unpaired Student’s t-test was used. Statistical significance is indicated as follows: ∗ p < 0.05, ∗ ∗ p < 0.01, ∗ ∗ ∗ p < 0.001. All treatments used EGF at 10 ng/mL and LA3IK at 80 μM.

Article Snippet: Quantification of secretory ANGPTL4 and VEGF in the culture medium was performed using a Human Enzyme-Linked Immunosorbent Assay (ELISA) development kit (DY3458 and DVE00) following the manufacturer’s instructions (R&D Systems).

Techniques: RNA Sequencing, Control, Inhibition, Expressing, Enzyme-linked Immunosorbent Assay, Two Tailed Test, MANN-WHITNEY